|Tested species reactivity||Human, Mouse|
|Published species reactivity||Human, Not Applicable|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Human Villin protein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:50-1:100|
|Western Blot (WB)||1-3 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-12227 targets Villin in IHC (P) applications and shows reactivity with Human samples.
The MA5-12227 immunogen is human Villin protein.
Villin can cap, nucleate, sever and bundle actin in a Ca and phosphoinositide-regulated manner. It is associated with the microvillar actin core bundle of intestinal and renal brush border implicated in adsorption. Villin is composed of six repeats, each containing 150 residues that together constitute the core domain followed by the carboxyl-terminal headpiece domain of 87 residues. The core domain retains the Ca dependent capping nucleating and severing activity, whereas the headpiece domain contributes towards actin filament bundling and binding F-actin, independently of Ca
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Oncogenic transformation of diverse gastrointestinal tissues in primary organoid culture.
MA5-12227 was used in immunohistochemistry - paraffin section to study the oncogenic transformation in primary organoid culture of gastrointestinal tissues
|Li X,Nadauld L,Ootani A,Corney DC,Pai RK,Gevaert O,Cantrell MA,Rack PG,Neal JT,Chan CW,Yeung T,Gong X,Yuan J,Wilhelmy J,Robine S,Attardi LD,Plevritis SK,Hung KE,Chen CZ,Ji HP,Kuo CJ||Nature medicine (20:769)||2014|
Pulmonary enteric adenocarcinoma: a study of the clinicopathologic and molecular status of nine cases.
MA5-12227 was used in immunohistochemistry to report on nine cases of pulmonary enteric adenocarcinoma
|Wang CX,Liu B,Wang YF,Zhang RS,Yu B,Lu ZF,Shi QL,Zhou XJ||International journal of clinical and experimental pathology (7:1266)||2014|